Publicaciones científicas

/cun/investigacion/publicaciones-cientificas/areaMain/02
  • Study on the nutritional status and feeding habits in school-children in Madrid City (Spain) during the economic crisis

    Moreno Villares JM (1), Sáenz de Pipaón M, Carrasco Sanz Á, Díaz Martín JJ, Redecillas Ferreiro S, Moráis López A, Sánchez Valverde F, Navas López V, San José González MÁ, Leis Trabazo R, Gil-Campos M, Blesa Baviera LC, Campoy Folgoso C.

    (1) Clínica Universidad de Navarra.

    Nutrición Hospitalaria 05 de OCTUBRE de 2018

  • Daratumumab más lenalidomida y dexametasona versus lenalidomida y dexametasona en el mieloma múltiple recurrente o refractario

    Dimopoulos MA (1), San-Miguel J (2), Belch A (3), White D (4), Benboubker L (5), Cook G (6), Leiba M (7), Morton J (8), Ho PJ (9), Kim K (10), Takezako N (11), Moreau P (12), Kaufman JL (13), Sutherland HJ (14), Lalancette M (15), Magen H (16), Iida S (17), Kim JS (18), Prince HM (19), Cochrane T (20), Oriol A (21), Bahlis NJ (22), Chari A (23), O' Rourke L (24), Wu K (24), Schecter JM (25), Casneuf T (26), Chiu C (24), Soong D 24, Sasser AK (27), Khokhar NZ (24), Avet-Loiseau H (28), Usmani SZ (29).

    (1) The National and Kapodistrian University of Athens, Athens, Greece
    (2) Clínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain.
    (3) Department of Oncology, University of Alberta Cross Cancer Institute, Edmonton, Alberta, Canada.
    (4) QEII Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada.
    (5) Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France.
    (6) St James Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds.
    (7) Sheba Medical Center, Tel Hasher, Ramat Gan, Israel.
    (8) Icon Cancer Care, South Brisbane, QLD, Australia.
    (9) Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
    (10) Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul.
    (11) Dept of Hematology, National Hospital Organization Disaster Medical Center of Japan, Tachikawa.
    (12) Hematology, University Hospital Hôtel-Dieu, Nantes, France.
    (13) Winship Cancer Institute, Emory University, Atlanta, GA, USA.
    (14) Leukemia/Bone Marrow Transplant Program, University of British Columbia, Vancouver, British Columbia.
    (15) CHU de Québec Research Center, Faculty of Medicine, Laval University, Québec, Canada.
    (16) Institute of Hematol, Davidoff Cancer Center, Beilinson Hospital, Rabin Medical Center, Petah-Tikva.
    (17) Dept of Hematology/Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya.
    (18) Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea.
    (19) Epworth HealthCare and Sir Peter MacCallum Department of Oncology, University of Melbourne.
    (20) Gold Coast University Hospital, Southport, QLD, Australia.
    (21) Institut Catalá Oncologia,Institut Josep Carreras,Hospital Germans Trias I Pujol, Barcelona.
    (22) University of Calgary, Arnie Charbonneau Cancer Institute, Calgary, AB, Canada.
    (23) Icahn School of Medicine at Mount Sinai, New York, NY, USA.
    (24) Janssen Research & Development, LLC, Spring House, PA, USA.
    (25) Janssen Research & Development, LLC, Raritan, NJ, USA.
    (26) Janssen Research & Development, Beerse, Belgium.
    (27) Genmab US, Inc, Princeton, NJ, USA.
    (28) Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France.
    (29) Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.

    Haematologica 20 de SEPTIEMBRE de 2018

  • Is there a role for HIPEC in ovarian cancer?

    Harter P (1), du Bois A (2), Sehouli J (3), Mahner S (4), Vergote I (5), Chiva L (6), Gonzalez-Martin A (7), Fotopoulou C (3,8).

    (1) Department of Gynecology, Kliniken Essen Mitte, Essen and Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group, Essen, Germany.
    (2) Department of Gynecology, Kliniken Essen Mitte, Essen and Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group, Essen, Germany.
    (3) Department of Gynecology, Charité Medical University of Berlin, Germany and North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group and AGO Study Group, Berlin, Germany.
    (4) Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich and AGO Study Group, Munich, Germany.
    (5) University Hospitals Leuven and BGOG, Leuven, Belgium.
    (6) Department of Obstetrics and Gynecology, Clínica Universidad de Navarra and GEICO Study Group, Madrid, Spain.
    (7) Department of Medical Oncology, Clínica Universidad de Navarra and GEICO Study Group, Madrid, Spain.
    (8) Department of Surgery and Cancer, Gynecologic Oncology, Hammersmith Hospital, Imperial College, London, UK.

    Archives of Gynecologic and Obstetrics 20 de SEPTIEMBRE de 2018

  • Increased Oral Bioavailability of Resveratrol by Its Encapsulation in Casein Nanoparticles

    Peñalva R (1), Morales J (2), González-Navarro CJ (3), Larrañeta E (4), Quincoces G (5), Peñuelas I (6), Irache JM (7).

    (1) NANO-VAC Research Group, Department of Pharmacy and Pharmaceutical Technology, University of Navarra, 31008 Pamplona, Spain.
    (2) NANO-VAC Research Group, Department of Pharmacy and Pharmaceutical Technology, University of Navarra, 31008 Pamplona, Spain. 
    (3) Centre for Nutrition Research, University of Navarra, 31080 Pamplona, Spain. 
    (4) NANO-VAC Research Group, Department of Pharmacy and Pharmaceutical Technology, University of Navarra, 31008 Pamplona, Spain.
    (5) Radiopharmacy Unit, Department of Nuclear Medicine, Clinica Universidad de Navarra, University of Navarra, 31008 Pamplona, Spain.
    (6) Radiopharmacy Unit, Department of Nuclear Medicine, Clinica Universidad de Navarra, University of Navarra, 31008 Pamplona, Spain. 
    (7) NANO-VAC Research Group, Department of Pharmacy and Pharmaceutical Technology, University of Navarra, 31008 Pamplona, Spain.

    International Journal of Molecular Sciences 18 de SEPTIEMBRE de 2018

  • Riesgo de cáncer de endometrio e hiperplasia endometrial con atipia en mujeres posmenopáusicas asintomáticas con grosor endometrial ≥11 mm

    Alcázar JL (1), Bonilla L (2), Marucco J (3), Padilla AI (4), Chacón E (1), Manzour N 1, Salas A (1).

    (1) Department of Obstetrics and Gynecology, Clínica Universidad de Navarra, School of Medicine, University of Navarra, Pamplona, Spain.
    (2) Department of Obstetrics and Gynecology, University Hospital Virgen de las Nieves, Granada, Spain.
    (3) Centro de Diagnóstico TCBA, Buenos Aires, Argentina.
    (4) Department of Obstetrics and Gynecology, Canaty Islands University Hospital, Tenerife, Spain.

    Journal Clinical of Ultrasound 16 de AGOSTO de 2018

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra